A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
Clinical trial NCT06499688 · COMPLETED
Trial details
- NCT number
- NCT06499688
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-28
- Primary completion
- 2024-03-29
- Enrollment
- 529
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.